anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.89 [0.82, 0.95]< 125%58 studies (58/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.79 [0.50, 1.24]< 10%2 studies (2/-)84.9 %some concernnot evaluable moderatecrucial-
deaths 0.90 [0.86, 0.94]< 119%96 studies (96/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.81 [0.68, 0.97]< 138%13 studies (13/-)99.0 %some concernlow moderatecrucial-
clinical deterioration 0.71 [0.58, 0.86]< 149%21 studies (21/-)100.0 %some concernlow moderateimportant-
clinical improvement 1.16 [1.04, 1.29]> 140%25 studies (25/-)99.7 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.32 [0.95, 1.83]> 150%7 studies (7/-)94.9 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.51 [1.04, 2.17]> 151%9 studies (9/-)98.5 %some concernserious moderateimportant-
clinical improvement (7-day) 1.54 [0.73, 3.22]> 170%4 studies (4/-)87.3 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.11 [1.01, 1.22]> 120%13 studies (13/-)98.9 %some concerncritical moderateimportant-
death or ventilation 0.90 [0.84, 0.96]< 158%23 studies (23/-)100.0 %some concerncritical moderateimportant-
hospital discharge 1.07 [1.00, 1.15]> 163%12 studies (12/-)97.1 %some concerncritical moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.89 [0.81, 0.99]< 116%27 studies (27/-)98.6 %some concerncritical moderateimportant1
radiologic improvement (14-day) 3.02 [1.77, 5.14]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
viral clearance 2.88 [1.09, 7.63]> 190%5 studies (5/-)98.3 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.18 [0.54, 2.54]> 183%2 studies (2/-)66.0 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.01 [0.04, 28.87]> 198%4 studies (4/-)